<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475367</url>
  </required_header>
  <id_info>
    <org_study_id>5701-19</org_study_id>
    <nct_id>NCT04475367</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of an APP in Improving Treatment Adherence in Hypertensive Patients in Hypertension Ambulatory</brief_title>
  <official_title>Evaluation of the Effect of an APP in Improving Treatment Adherence in Hypertensive Patients in Hypertension Ambulatory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiologia do Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Cardiologia do Rio Grande do Sul</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief Summary: Through the App, the user will have the opportunity to connect directly with
      the health professional, clarify doubts and manage the treatment of their hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate treatment adherence and blood pressure reduction, through the HiperCross App,
      between two groups of hypertensive patients in a Hypertension Public Ambulatory in Porto
      Alegre.

      The investigators hope to identify better adherence to treatment, as well as a significant
      reduction in blood pressure, all of these results will be better evaluated using the
      HiperCross application.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 10, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The participants will be randomized into 2 intervention groups</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>blind research assistant</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure value</measure>
    <time_frame>15 minutes</time_frame>
    <description>systolic Blood pressure and dyastolic Blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morisky scale</measure>
    <time_frame>15 minutes</time_frame>
    <description>Medication adherence. The Morisky scale condition and medication specific assessment: 1) measures the level of adherence an medication, 2) measures the severity of Major Depressive Disorder, a determinant of non-adherence 3) identifies why the patient is not taking their medication, 4) determines the risk between non-adherence to BP measures of disease control. 0-1 = Low motivation; 2-3 = High motivation / 0-1 = Low knowledge; 2-3 = High knowledge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Adhesion</condition>
  <arm_group>
    <arm_group_label>hypertensive patients using HyperCrossApp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interdisciplinary health care
+ HyperCross App</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertensive patients without using HyperCrossApp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interdisciplinary health care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>App hypercross group</intervention_name>
    <description>hypertensive patients using HyperCrossApp</description>
    <arm_group_label>hypertensive patients using HyperCrossApp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>without App hypercross group</intervention_name>
    <description>Interdisciplinary health care</description>
    <arm_group_label>hypertensive patients without using HyperCrossApp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypertensive patients admitted to the hypertension clinic at Instituto de Cardiologia

          -  older 18 years

        Exclusion Criteria:

          -  Patients without a mobile phone compatible with the App
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruna Eibel, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Post Graduation professor - Cardiology Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Paula Reis, Nurse</last_name>
    <phone>+555132303600</phone>
    <email>areis9874@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruna Eibel, PhD</last_name>
    <phone>+555132303600</phone>
    <email>brunaeibel@gmail.com</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 18, 2020</last_update_submitted>
  <last_update_submitted_qc>July 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Cardiologia do Rio Grande do Sul</investigator_affiliation>
    <investigator_full_name>Ana Paula Reis</investigator_full_name>
    <investigator_title>Nurse Specialist</investigator_title>
  </responsible_party>
  <keyword>software</keyword>
  <keyword>hypertension</keyword>
  <keyword>technology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

